Anti-infective monoclonal antibodies: perils and promise of development
Identifieur interne : 000F78 ( Main/Exploration ); précédent : 000F77; suivant : 000F79Anti-infective monoclonal antibodies: perils and promise of development
Auteurs : Janice M. Reichert [États-Unis] ; Matthew C. Dewitz [États-Unis]Source :
- Nature Reviews Drug Discovery [ 1474-1776 ] ; 2006-03.
Abstract
So far, most monoclonal antibodies have been developed for treating cancer or immunological diseases. However, the global spread of infections such as West Nile and corona viruses, and the need to address the potential threat of bioterrorism, has boosted public interest in, and government support of, counter-measures for infectious diseases. The attractive features of monoclonal antibodies, such as high specificity and effective recruitment of the immune system, would seem to make them excellent candidates as anti-infective agents. Here, we analyse trends in the development and approval of anti-infective monoclonal antibodies, and discuss factors that influence their success.
Url:
DOI: 10.1038/nrd1987
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000648
- to stream Istex, to step Curation: 000628
- to stream Istex, to step Checkpoint: 000245
- to stream Main, to step Merge: 000F84
- to stream Main, to step Curation: 000F78
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-infective monoclonal antibodies: perils and promise of development</title><author><name sortKey="Reichert, Janice M" sort="Reichert, Janice M" uniqKey="Reichert J" first="Janice M." last="Reichert">Janice M. Reichert</name></author><author><name sortKey="Dewitz, Matthew C" sort="Dewitz, Matthew C" uniqKey="Dewitz M" first="Matthew C." last="Dewitz">Matthew C. Dewitz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:388076B331C8B8E2AA15A9BBD8211E4EDB751F8B</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1038/nrd1987</idno><idno type="url">https://api.istex.fr/ark:/67375/GT4-RVN71VMH-6/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000648</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000648</idno><idno type="wicri:Area/Istex/Curation">000628</idno><idno type="wicri:Area/Istex/Checkpoint">000245</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000245</idno><idno type="wicri:doubleKey">1474-1776:2006:Reichert J:anti:infective:monoclonal</idno><idno type="wicri:Area/Main/Merge">000F84</idno><idno type="wicri:Area/Main/Curation">000F78</idno><idno type="wicri:Area/Main/Exploration">000F78</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Anti-infective monoclonal antibodies: perils and promise of development</title><author><name sortKey="Reichert, Janice M" sort="Reichert, Janice M" uniqKey="Reichert J" first="Janice M." last="Reichert">Janice M. Reichert</name><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Janice M. Reichert is at Tufts University, Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, Massachusetts 02111</wicri:regionArea><wicri:noRegion>Massachusetts 02111</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author><author><name sortKey="Dewitz, Matthew C" sort="Dewitz, Matthew C" uniqKey="Dewitz M" first="Matthew C." last="Dewitz">Matthew C. Dewitz</name><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Matthew C. Dewitz is at New York University School of Law, 40 Washington Square, New York, New York 10013</wicri:regionArea><wicri:noRegion>New York 10013</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Nature Reviews Drug Discovery</title><idno type="ISSN">1474-1776</idno><idno type="eISSN">1474-1784</idno><imprint><publisher>Nature Publishing Group</publisher><date when="2006-03">2006-03</date><biblScope unit="vol">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="191">191</biblScope><biblScope unit="page" to="195">195</biblScope><date type="Copyright" when="2006">2006</date></imprint><idno type="ISSN">1474-1776</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1474-1776</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">So far, most monoclonal antibodies have been developed for treating cancer or immunological diseases. However, the global spread of infections such as West Nile and corona viruses, and the need to address the potential threat of bioterrorism, has boosted public interest in, and government support of, counter-measures for infectious diseases. The attractive features of monoclonal antibodies, such as high specificity and effective recruitment of the immune system, would seem to make them excellent candidates as anti-infective agents. Here, we analyse trends in the development and approval of anti-infective monoclonal antibodies, and discuss factors that influence their success.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Reichert, Janice M" sort="Reichert, Janice M" uniqKey="Reichert J" first="Janice M." last="Reichert">Janice M. Reichert</name></noRegion><name sortKey="Dewitz, Matthew C" sort="Dewitz, Matthew C" uniqKey="Dewitz M" first="Matthew C." last="Dewitz">Matthew C. Dewitz</name><name sortKey="Reichert, Janice M" sort="Reichert, Janice M" uniqKey="Reichert J" first="Janice M." last="Reichert">Janice M. Reichert</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:388076B331C8B8E2AA15A9BBD8211E4EDB751F8B
|texte= Anti-infective monoclonal antibodies: perils and promise of development
}}
| This area was generated with Dilib version V0.6.33. |  |